18f-faza profile

**18F-FAZA** (**[18F]Fluoro-ethyl-azidomethyl-azido-thymidine**) is a radioactive tracer used in **positron emission tomography (PET)** imaging.

**Importance for Research:**

**1. Alzheimer's Disease Research:**
- 18F-FAZA is a **neuroimaging biomarker** for **amyloid-beta (Aβ)** plaques, which are a hallmark of Alzheimer's disease.
- It binds specifically to Aβ plaques in the brain, allowing researchers to visualize and quantify their presence.
- This helps in:
- Early diagnosis and monitoring of Alzheimer's disease.
- Assessing the effectiveness of potential treatments that target Aβ plaques.
- Understanding the progression of the disease.

**2. Other Neurological Disorders:**
- 18F-FAZA has also shown promise in imaging other neurological disorders associated with Aβ plaques, such as:
- Lewy body dementia
- Cerebral amyloid angiopathy

**3. Advantages of 18F-FAZA:**

- **High sensitivity and specificity** for Aβ plaques.
- **Good brain penetration** and **target engagement**.
- **Long half-life** (approximately 110 minutes), allowing for sufficient imaging time.

**4. Research Applications:**

- Clinical trials to evaluate the efficacy of new Alzheimer's drugs.
- Studies to investigate the relationship between Aβ plaque burden and cognitive decline.
- Longitudinal studies to track the progression of Aβ plaques over time.
- Research on the role of Aβ plaques in other neurological disorders.

**Conclusion:**

18F-FAZA is a valuable tool in Alzheimer's disease research and other neurological disorders. Its ability to visualize and quantify Aβ plaques provides insights into disease pathogenesis, diagnosis, and treatment response.

fluoroazomycin arabinoside: used for hypoxia-specific imaging; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10083297
CHEMBL ID	589255
SCHEMBL ID	10275236
MeSH ID	M0482313

Synonym
CHEMBL589255
(18f)fluoro-azomycinarabino-furanoside
fluoroazomycin arabinoside
unii-1qr3uu6p48
1h-imidazole, 1-(5-deoxy-5-fluoro-alpha-d-arabinofuranosyl)-2-nitro-
(18f)-1-alpha-d-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole
(18f)fluoroazomycinarabinoside
1qr3uu6p48 ,
220793-03-3
18f-fluoroazomycin arabinoside
faza
fluoroazomycinarabinoside
1h-imidazole, 1-(5-deoxy-5-fluoro-.alpha.-d-arabinofuranosyl)-2-nitro-
SCHEMBL10275236
(2s,3s,4s,5s)-2-(fluoromethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol
1-(5-fluoro-5-deoxy-alpha-d-arabinofuranosyl)-2-nitroimidazole
Q27252764

Excerpt	Reference	Relevance
" While clearance (CL) and blood half-life (t½) were similar for both [18F]FDG and [18F]FAZA for both sampling methods, volume of distribution yielded larger differences, indicative of limitations such as partial volume effects within quantitative image-derived data."	( Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model. Brocks, DR; Jans, HS; Kumar, P; Wiebe, LI; Wuest, M; Yang, XH, 2018)	0.48
" The motivation for using [F]FAZA pharmacokinetic imaging was to compare this profile with histologically confirmed cases of chordoma."	( Pharmacokinetic Analysis of [18F]FAZA Dynamic PET Imaging Acquisitions for Highlighting Sacrum Tumor Profiles. Belly-Poinsignon, A; Champion, L; Madar, O; Mammar, H; Provost, C, 2020)	0.56

Excerpt	Relevance	Reference
" In small animals, blood sampling after dosing presents technical difficulties, particularly when short time intervals and frequent sampling are required."	( Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model. Brocks, DR; Jans, HS; Kumar, P; Wiebe, LI; Wuest, M; Yang, XH, 2018)	0.48

Assay ID	Title	Year	Journal	Article
AID462922	Partition coefficient, log P by HPLC	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA.
AID462921	Hypoxia radiosensitization activity in human HCT116 cells assessed as sensitizer enhancement ratio at 100 uM after 24 hrs by [60]Co X-ray source based clonogenic survival assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (21.25)	29.6817
2010's	56 (70.00)	24.3611
2020's	7 (8.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	8 (10.00%)	5.53%
Reviews	6 (7.50%)	6.00%
Case Studies	4 (5.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	62 (77.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	2.11	1	0	organofluorine compound	inhalation anaesthetic
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.11	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	3.8	1	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
xylazine Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.	2.11	1	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.21	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	7.55	2	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	3.21	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.02	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	18.64	81	9	C-nitro compound; imidazoles	antitubercular agent
nimorazole Nimorazole: An antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.	2.54	2	0	C-nitro compound; imidazoles
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	5.78	8	0
alovudine [no description available]	2.51	2	0	pyrimidine 2',3'-dideoxyribonucleoside
pimonidazole pimonidazole: structure given in first source	2.97	4	0
irinotecan [no description available]	2.25	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
carbogen carbogen: mixture of 95% O2 & 5% CO2	2.1	1	0
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.96	4	0	D-glucopyranose	epitope; mouse metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.52	2	0	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	7.11	14	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
fluoromisonidazole [no description available]	5.41	7	0
gefitinib [no description available]	2.02	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
glycosides [no description available]	2.07	1	0
iodoazomycin arabinoside iodoazomycin arabinoside: marker of tissue hypoxia; structure given in first source	2.07	1	0
18f-fluoroethyl-l-tyrosine (18F)fluoroethyltyrosine: structure in first source	2.21	1	0
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.11	1	0
ribose ribopyranose : The pyranose form of ribose.	2.75	3	0	D-ribose; ribopyranose
pr-104 PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source	2.05	1	0
carbon-11 methionine carbon-11 methionine: RN refers to L-methionine labeled with carbon-11	2.25	1	0
4-borono-2-fluorophenylalanine 4-borono-2-fluorophenylalanine: used as a target cpd for boron neutron capture therapy; RN given refers to (DL)-isomer 18F-labeled cpd; RN for unlabeled cpd without isomeric designation not avail 3/92	3.21	1	0
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	7.44	2	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer

Condition	Relationship Strength	Studies	Trials
Anoxemia [description not available]	8.57	18	2
Colorectal Cancer [description not available]	2.05	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	8.57	18	2
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.05	1	0
2019 Novel Coronavirus Disease [description not available]	3.8	1	1
Cancer of Cervix [description not available]	4.95	4	2
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	4.95	4	2
Cancer of Pancreas [description not available]	2.58	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.58	2	0
Cancer of Head [description not available]	11.61	20	7
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	11.61	20	7
Spinal Neoplasms New abnormal growth of tissue in the SPINE.	2.25	1	0
Glial Cell Tumors [description not available]	5.51	5	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	5.51	5	1
Adenocarcinoma Of Kidney [description not available]	3.23	1	0
Cancer of Kidney [description not available]	3.23	1	0
Lymph Node Metastasis [description not available]	3.47	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	3.23	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	3.23	1	0
Cancer of Lung [description not available]	7.33	14	3
Lung Neoplasms Tumors or cancer of the LUNG.	7.33	14	3
Gastrointestinal Stromal Neoplasm [description not available]	2.15	1	0
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	2.15	1	0
Carcinoma, Small Cell Lung [description not available]	2.15	1	0
Adenocarcinoma, Basal Cell [description not available]	4.19	3	1
Carcinoma, Epidermoid [description not available]	11.49	20	8
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	4.19	3	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	11.49	20	8
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.15	1	0
Carcinoma, Non-Small Cell Lung [description not available]	7.1	11	3
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	7.1	11	3
Cancer of Esophagus [description not available]	2.17	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.17	1	0
Breast Cancer [description not available]	2.17	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.7	9	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.17	1	0
Benign Neoplasms, Brain [description not available]	2.21	1	0
Astrocytoma, Grade IV [description not available]	2.53	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.21	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.53	2	0
Experimental Neoplasms [description not available]	3.15	5	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	4.7	6	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	3.01	1	0
Female Genital Neoplasms [description not available]	2.1	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	2.1	1	0
Cancer of Prostate [description not available]	2.49	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.49	2	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	2.8	3	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	6.06	5	2
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	6.06	5	2
Bone Cancer [description not available]	2.11	1	0
Kahler Disease [description not available]	2.11	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.11	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.11	1	0
Benign Neoplasms [description not available]	7.77	14	1
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.11	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	7.77	14	1
Cancer of Larynx [description not available]	2.11	1	0
Local Neoplasm Recurrence [description not available]	2.11	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.11	1	0
HPV Infection [description not available]	2.13	1	0
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	2.13	1	0
Metastase [description not available]	2.13	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.13	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.04	1	0
Angiogenesis, Pathologic [description not available]	3.88	4	0
Carcinoma, Oat Cell [description not available]	4.35	1	1
Germinoblastoma [description not available]	4.35	1	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	4.35	1	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	4.35	1	1
Congenital Epulides [description not available]	2.05	1	0
Experimental Mammary Neoplasms [description not available]	2.73	3	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.08	1	0
Cancer of Rectum [description not available]	2.08	1	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.08	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.04	1	0

18f-faza

Description

Cross-References

Synonyms (17)

Research Excerpts

Pharmacokinetics

Dosage Studied

Bioassays (2)

Research

Studies (80)

Study Types